Veteran broadcaster Jane King from the NASDAQ MarketSite in Times Square interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing NRx-101 – the first investigational drug in FDA trials for suicidal bipolar depression.
Broadcasts
Nov. 20, 2023
Jane King, NASDAQ MarketSite interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals
Top Health Officials Meet to Discuss Pause of Johnson & Johnson Vaccine
Cheddar News – Apr 15, 2021 12:02 am
FDA Investigating Quality Issues That Led To Millions Of J&J Vaccines To Be Thrown Out
Cheddar News – Apr 2, 2021 02:23 pm
New COVID 19 Drug can Effectively Treat Patients – Discussion with Dr. Javitt, CEO NeuroRx
Interview with Dr. Yo – Streamed live on Feb 11, 2021
New COVID-19 drug used to treat patients suffering from respiratory failure is in trials
Fox Business Apr. 07, 2021 – 5:06 – NeuroRX CEO Dr. Jonathan Javitt discusses the new COVID-19 drug for respiratory distress and vaccine boosters.
Focusing on You: UM Tests Drug to Lessen Severity of COVID-19
University of Miami Health System
- 1
- 2